SC
NVAX icon

Sculptor Capital’s Novavax NVAX Stock Holding History

Sculptor Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-303,200
Closed -$2.1M – 467
2023
Q1 		$2.1M Buy
+303,200
New +$2.79M 0.05% 205

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sculptor Capital's NVAX Position: Q1 2025 in Review

Sculptor Capital sold out of Novavax (NVAX) in Q1 2025, closing a stake of 200 shares — an estimated $1.65K sold.

Sculptor Capital first reported a position in NVAX in Q4 2022 and held it in 7 quarters. The position peaked at $5.9M in Q4 2022. 245 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • Sculptor Capital reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • Sculptor Capital sold 200 Novavax shares in Q1 2025, an estimated $1.65K.
  • Sculptor Capital first reported a position in Novavax in Q4 2022 and held it in 7 quarters.
  • Sculptor Capital's Novavax position peaked at $5.9M in Q4 2022.
  • 245 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on Sculptor Capital's 13F filing for Q1 2025, filed 15 May 2025.